Search

Your search keyword '"Usiskin, K"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Usiskin, K" Remove constraint Author: "Usiskin, K"
48 results on '"Usiskin, K"'

Search Results

1. New insights into the genetic etiology of Alzheimer's disease and related dementias

2. Ozanimod as induction and maintenance therapy for ulcerative colitis

3. Artificial intelligence in inflammatory bowel disease endoscopy: implications for clinical trials

9. Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices

15. Genetic architecture of human plasma lipidome and its link to cardiovascular disease

16. Genetic architecture of human plasma lipidome and its link to cardiovascular disease

18. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

20. P336 Efficacité et tolérance de la canagliflozine chez des diabétiques de type 2 (DT2) mal contrôlés par metformine plus sulfamide hypoglycémiant sur une période de 52 semaines

24. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

25. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

27. Considerations for Colorectal Neoplasia Detection in Inflammatory Bowel Disease Clinical Trials.

28. Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions.

29. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.

30. Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments.

31. Reply.

32. Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.

33. Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.

34. Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.

35. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.

36. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.

37. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.

38. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.

39. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).

40. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.

41. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.

42. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.

43. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

44. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.

45. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.

46. T lymphocyte surface antigen markers in osteoporosis.

47. Lack of effect of dehydroepiandrosterone in obese men.

48. Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms.

Catalog

Books, media, physical & digital resources